Tarsus Pharmaceuticals adds former Allergan CEO David Pyott to board

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) appointed David E. I. Pyott, former Chairman and CEO of Allergan, Inc., to its Board of Directors, the company announced February 18.

Pyott served as CEO of Allergan for 17 years, during which he transformed the company from an eye care business with approximately $1 billion in sales into a global specialty pharmaceutical and medical device company generating more than $7 billion in revenue. Before Allergan, he served as Head of the Novartis Nutrition Division and as a member of the Executive Committee of Novartis AG.

"David is one of the most accomplished leaders in eye care, with a strong track record of translating innovation into global impact," said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. "His experience building some of the most successful franchises in our industry will be invaluable as we scale XDEMVY, advance our pipeline and position Tarsus for sustained growth."

Pyott currently serves on the boards of Alnylam Pharmaceuticals and Pliant Therapeutics. He previously served on the Supervisory Board of Royal Philips in the Netherlands and the Board of Directors of BioMarin Pharmaceutical Inc.

"Tarsus is entering a highly compelling next phase of its evolution, and I'm pleased to join the Board at this important moment in time," Pyott said. "I look forward to working with its outstanding Board and management team to help build long-term value and advance further meaningful innovation in eye care and beyond."

Tarsus markets XDEMVY (lotilaner ophthalmic solution) 0.25%, which is FDA approved for the treatment of Demodex blepharitis. The company is developing TP-04 for ocular rosacea and TP-05 as an oral tablet for Lyme disease prevention, both in Phase 2 trials.

The information in this article is based on a company press release.

You May Also Be Interested In

• Tarsus Pharmaceuticals (TARS) PT Lowered to $89 at Guggenheim
• Landstar names Bill Clement as chief commercial officer
• Everbright Digital prices $8.07M public offering at $1.88 per share